Background {#Sec1}
==========

Variation found in noncoding regions of the genome is much more abundant and, perhaps, even more relevant than coding variation for certain human traits, but its biological meaning is hard to assess \[[@CR1]\]. It has been noticed that between 34 and 88 % of the disease-associated variants detected by genome-wide association studies (GWAS) appear to cluster in noncoding regions of the genome, specifically in DNase-I hypersensitivity sites (DHSs) \[[@CR2]\], and that some of the DHSs exhibit allele-specificity \[[@CR2]--[@CR4]\]. Chromatin remodeling processes, for example those associated with the transcription machinery, create openings in the chromatin, which can be detected as DHSs, that allow transcription factors to interact with the underlying DNA. Hence DHSs tend to correlate with known *cis*-acting regulatory elements, such as promoters and transcription factor binding sites \[[@CR5]\].

We have been investigating a systematic approach that uses DHSs to determine if noncoding single-nucleotide variation changes the local allele-specific chromatin accessibility, something that would indicate a potential regulatory role for a variant \[[@CR6]\]. We have also developed a variance component based burden test to determine the contribution of localized relationship kernels to the trait variance \[[@CR7], [@CR8]\]. Here, we test if by combining both lines of research we could detect potential *cis*-acting regulatory loci. Our approach differs from previous works \[[@CR4], [@CR9]\] in that (a) we evaluate the association of each expression phenotype against a single covariance kernel, in a 1 degree of freedom test, and (b) we use an allele-specific chromatin accessibility measure to filter and weight the variants.

Methods {#Sec2}
=======

Data set {#Sec3}
--------

We used single-nucleotide polymorphism (SNP) dosages from 959 genotyped individuals, transcript expression levels from 647 of those individuals, and the genealogies (1389 individuals in 20 families) that were provided as part of the Genetic Analysis Workshop 19 (GAW19) family-based data set \[[@CR10]\]. In addition, we used publicly available data from a CEU-CEPH (Northern Europeans from Utah--Centre d'Etude du Polymorphisme Humain) female's peripheral blood mononucleated cells, NA12878, and its derived lymphoblastoid cell line, GM12878. The specific data used were: whole genome sequencing (WGS) genotypes for NA12878, from Illumina's Platinum Genomes \[[@CR11]\], and mapped short-sequencing reads (reads) from all five replicates of the DHSs sequencing (DNase-seq) of GM12878, from ENCODE \[[@CR12]\], were used in this study. Physical coordinates and annotations for genes, transcripts, and marker loci refer to release 19 of the human genome (hg19) from the University of California, Santa Cruz (UCSC).

Reference panel of heterozygous single-nucleotide polymorphism loci {#Sec4}
-------------------------------------------------------------------

We compiled a reference panel of heterozygous SNP sites from the genotype calls from the high-coverage/high-quality WGS of NA12878. This independent genotypes source allowed us to analyze heterozygous loci where, because of either low coverage or complete allele-specific accessibility, only 1 allele is represented in the DNase-seq reads.

Chromatin accessibility measurement {#Sec5}
-----------------------------------

We defined our chromatin accessibility measure to be equal to the DNase-seq read depth of each allele at a heterozygous locus. Based on our previous experience \[[@CR6]\] the DNase-seq reads from all five GM12878 replicates were pooled to increase the total sequencing coverage at the DHSs. Samtools \[[@CR13]\] mpileup was then used to obtain genotype calls only for loci in the known NA12878 heterozygous reference panel, and allele-specific read depths were obtained from the count of forward and reverse mapped reference and alternative allele annotations stored in the DP4 tag of the generated variant call format (VCF) file.

Functional potential {#Sec6}
--------------------

A departure from the expectation of an equal chromatin accessibility measurement of the two alleles at a locus within a DHS is what we refer to as the locus functional potential (FP). We implemented the FP statistic as a likelihood ratio--based test that contrasts the observed allele read depths with their expected depth at known heterozygous loci within DHSs \[[@CR6]\]. A significant bias toward 1 allele in the chromatin accessibility measure of a locus can indicate a putative allele-specific chromatin remodeling event that compromised the footprint left by a DHS. We estimated the FP for all known NA12878 heterozygous loci that were present in the DNase-seq of GM12878.

Trait and covariates {#Sec7}
--------------------

To test our approach we used the real expression phenotypes from approximately 20,000 transcripts provided in the GAW19 family data set \[[@CR10]\]. In addition, we simulated 10,000 heritable quantitative phenotypes not associated with any of the SNP loci in the data set, using Sequential Oligogenic Linkage Analysis Routines (SOLAR) \[[@CR14]\], to evaluate the performance of our test under a null hypothesis.

We also used the sex, age, their interactions, and the smoking status at the first visit as covariates in all models. The first two principal components (PC1, PC2) (estimated as described in Peralta et al. \[[@CR7]\] and Almeida et al. \[[@CR8]\]), were added to account for any unknown population substructure that might be present.

Covariance kernels {#Sec8}
------------------

GAW19 SNP dosages were collected for all heterozygous loci from NA12878 with a FP estimate. Non informative loci were removed. A standardized dosages matrix, **Z**, was built from them, and the covariance matrix of the dosages, **R**, was obtained from$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \boldsymbol{R}=\boldsymbol{Z}\cdot {\boldsymbol{Z}}^T $$\end{document}$$

The covariance matrix was then scaled so that all diagonal elements were equal to 1, and the resulting matrix, **K**, was our nonweighted covariance kernel.

We also built a covariance kernel in which each locus contribution was weighted by its FP estimate. Because our FP statistic is a likelihood ratio test, we used the relative − loglikelihood from a locus against the sum of all loci − loglikelihoods as the locus weight, and thus all weights add up to 1. The covariance kernel, **K,** was constructed as before, with 1 exception. The covariance matrix of the dosages was obtained from$$\documentclass[12pt]{minimal}
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where ***D*** ~**w**~ is a diagonal matrix of weights.

Variance component model {#Sec9}
------------------------

We used the variance component model previously described in Peralta et al. \[[@CR7]\] and Almeida et al. \[[@CR8]\], in conjunction with the nonweighted and FP-weighted covariance kernels derived from the SNP dosages described above, to estimate the proportion of the phenotypic variance, *h* ~*geff*~^2^, explained by allele-specific genetic variants found within DHSs in an unrelated CEU-CEPH individual. The *h* ~*geff*~^2^ variance component, and its significance, was estimated for each real and simulated expression phenotype using SOLAR, a flexible genetic variance component analysis program with a focus on general pedigrees \[[@CR14]\].

Results {#Sec10}
=======

Our reference panel of heterozygous loci contained the 2,423,308 heterozygous SNPs that had been found in the WGS of NA12878. Only heterozygous loci are informative for allele-specific chromatin accessibility in a genome. Although heterozygous SNP sites can be directly inferred from DNase-seq data, it is not ideal, in part because of its very low coverage.

We were able to measure the allele-specific chromatin accessibility and estimate the FP for 48,236 (1.99 %) of those heterozygous SNPs but only 10,618 (22 %) of them were present in the GAW19 dosages. Of the 10,618 heterozygous-in-NA12878 SNPs with a FP estimation that were present in GAW19, 66 (0.62 %) were monomorphic in the GAW19 dosages and were therefore discarded from further analysis. The remaining 10552 SNPs with FP estimates were used for the construction of our weighted and nonweighted covariance kernels.

We conducted our variance component analysis of 10,000 simulated phenotypes using the weighted covariance kernel only and found no inflation or deflation of the *p* values of the estimated effects (Fig. [1](#Fig1){ref-type="fig"}), indicating that our test performed as expected when evaluated under the null hypothesis. Figure [2](#Fig2){ref-type="fig"} shows the frequency distribution of the weights.Fig. 1Quantile--quantile (Q-Q) plot of the *p* values obtained under a null hypothesis test. Analysis of 10,000 simulated phenotypes not associated with any of the GAW19 SNP loci. The obtained the *p* values follow the expected uniform distribution Fig. 2Frequency distribution of the weights used for variants in the weighted covariance kernel. Each weight represents the relative proportion of the functional potential − loglikelihood estimation of each variant in the kernel. The large proportion of variants in the first bin have a very small weight, and correspond to variants with a low confidence of having an allele-specific chromatin accessibility effect

We then analyzed the 20,527 transcript expression phenotypes in the GAW19 family data set using both the weighted and the nonweighted covariance kernels. After a genome-wide Bonferroni correction (−log~10~\[α\] = 5.6) we found significant evidence of potential *cis*-regulatory effects for ten transcripts (Table [1](#Tab1){ref-type="table"}). Eight of the transcripts were detected by both covariance kernels but two of them, GI_4506738-S and GI_15451941-S, were only found to be significant when the weighted covariance kernel was used. In most of the cases, the use of the nonweighted covariance kernel tended to slightly decrease the proportion of the transcript expression variance explained by the kernel, which was on average very high in both cases (*h* ~*geff*,*non* − *weighted*~^2^ = 0.6540, *h* ~*geff*, *weighted*~^2^ = 0.7046). While most of the trait heritability was explained by the covariance kernel, a substantial amount (between 14 and 28 %) still remained. Table [2](#Tab2){ref-type="table"} lists these ten transcripts along with their annotations and closest SNPs in the covariance kernels. Table [3](#Tab3){ref-type="table"} shows how the signal from our top result, GI_42544126-I, decreases when SNPs within the transcript region are progressively removed from the kernel.Table 1Transcripts for whom their variation in expression levels can be explained by a covariance kernel composed by SNP with FP estimates, at genome-wide significanceTranscriptCovariance kernelNon-weightedWeightedh2rh2r_pgeffgeff_ph2rh2r_pGeffgeff_pGI_42544126-I0.00000.50000.70744.03E-150.00000.50000.71454.55E-18GI_23097237-S0.00000.50000.78481.15E-140.00000.50000.74937.46E-12GI_10863968-S0.00000.50000.61095.68E-100.00000.50000.61229.05E-11Hs.283934-S0.07460.31380.83829.77E-100.14970.14430.76574.87E-09GI_12056480-A0.23570.04570.70691.69E-080.27920.01940.66285.43E-08GI_20986517-S0.00000.50000.76715.58E-080.00000.50000.77263.08E-08Hs.58104-S0.22300.07530.68866.89E-070.27050.03330.64158.47E-07GI_41393558-I0.00000.50000.53311.92E-060.00000.50000.53711.73E-06GI_4506738-SNA0.00000.50000.47586.66E-07GI_15451941-SNA0.26110.04410.60901.33E-06geff, Gene-specific effect estimate (*h* ^2^ ~geff~)geff_p, significance of the gene-specific effect estimateh2r, trait heritability estimate (*h* ^2^)h2r_p, significance of the trait heritability estimate Table 2Annotated transcript and SNP tableTranscriptGeneChromosomeStartLengthSNPDBSnp rsSNP annotationGI_42544126-ISF1chr11645320751424111_64511322rs2073798RASGRP2 intron11_64519345rs686171PYGM intron11_64546106rs3741398SF1 2 kb upstream, nc transcript variant, 5' UTR11_64546257rs1633462SF1 2 kb upstream, nc transcript variant, 5' UTR11_64573589rs669976MEN1 intron11_64576598rs67808744MEN1 intron11_64577620rs7949944MEN1 5' UTR, 2 kb upstreamGI_23097237-SCHST13chr3126243130190043_126218788rs6774768UROC1 intron3_126228953rs1873388UROC1 intron3_126242964rs1388096CHST13 2 kb upstream3_126245956rs4592980CHST13 intron/3'UTR3_126246370rs1994642CHST13 intron/3'UTR3_126247795rs11717719CHST13 intron3_126247848rs11718493CHST13 intronGI_10863968-SPOLD4chr1167119018203411_67196237rs1476792Hs.283934-STSPAN16chr19114068153085719_11340057rs1700124419_11358700rs480457919_11374675rs41623119_11380295rs480415919_11406952rs374409GI_12056480-AUTS2chr1790727162801_7710810rs58905635CAMTA1 intron1_7725855rs4908471CAMTA1 intron1_7749807rs3124797CAMTA1 intronGI_20986517-SMAPK8IP1chr11459070462097011_45838926rs1103866811_45840939rs711250511_45891418rs7123390CRY2 intronHs.58104-SFAM101Bchr17289771896017_185027rs1295143717_198698rs1186917417_206962rs11657163GI_41393558-IKIF1Bchr110270763978921_10270386rs3828081KIF1B 2 kb upstream1_10307453rs4240911KIF1B intron1_10438687rs1536262KIF1B 3'UTRGI_4506738-SRPS6KB2chr1167195934694511_67196237rs1476792RPS6KB2 intron11_67204342rs12787021PTPRCAP intron11_67213956rs210912311_67253564rs711002111_67258805rs75156711_67264679rs2276120GI_15451941-SUBA52chr1918682613565719_18499151rs105902219_18499238rs180482619_18715154rs72995445CRLF1 intron19_18859680rs11085244Gene symbols and coordinates for the ten transcripts that were detected as being potentially *cis*-regulated by SNPs in our covariance kernel. The closest SNPs to each gene are listed Table 3Decrease in the association signal when *cis*-located SNPs are removed from the kernelTranscriptGeneSNPs removed from the kernelCovariance kernelWeightedh2rgeffgeff_pnone0.00000.71454.55E-18GI_42544126-ISF12 in SF10.00000.68091.32E-12all in transcript region0.13490.13492.00E-05

Discussion {#Sec11}
==========

The objective of this study was to investigate the prioritization of SNPs based on their potential as functional, *cis*-acting, regulatory elements. To that end we used a combined approach that integrates functional information, in the form of allele-specific chromatin accessibility measurements at DHSs, gene expression phenotypes, and a variance component model that estimates the proportion of a trait's variance as a result of a localized relationship kernel.

We constructed nonweighted and weighted covariance kernels, using the 10,552 SNPs with an available FP estimate, and obtained the proportion of variance in the levels of transcript expression that could be explained by them in the family data set. We identified a clear signal for eight transcripts when using the nonweighted kernel, and for two additional transcripts when using the weighted kernel (see Table [1](#Tab1){ref-type="table"}). In contrast, we found no signals when we performed our analysis using the set of 10,000 simulated phenotypes; an indication that our test statistic was not artificially inflated when evaluated under the null hypothesis (see Fig. [1](#Fig1){ref-type="fig"}).

Some of our results are difficult to interpret because of the distance between the transcript location and the closest SNPs to it in our kernels. For transcripts GI_12056480-A and GI_15451941-S our results might indicate the presence of long-acting *cis*-elements, but could also be the result of, for example, linkage disequilibrium with SNPs in closer proximity to the transcript.

However, close examination of the annotations of the significant transcripts in our results shows suggestive evidence of potential *cis*-acting variants. Particularly for the GI_23097237-S, GI_42544126-I, GI_4506738-S, and GI_41393558-I transcripts, corresponding to the *CHST13*, *SF1*, *RP56KB2*, and *KIF1B* genes, respectively. The SNPs with FP estimates that we incorporated in our covariance kernel near these genes are all located either within the gene or within the promoter region of the gene (see Table [2](#Tab2){ref-type="table"}). The progressive removal of SNPs within and near the *SF1* gene led to the degradation of the signal from the GI_42544126-I transcript (see Table [3](#Tab3){ref-type="table"}), clearly suggesting a *cis*-acting effect of the variants in the transcript expression. Furthermore, previous research provides additional compelling evidence for the implication of rs11718493 in the allele-specific methylation of CpGs and the regulation of *CHST13* \[[@CR15], [@CR16]\], a carbohydrate sulfotransferase that is present in the Golgi membrane \[[@CR17]\], and rs1536262 has been reported to be a likely candidate for the regulation of *KIF1B* expression \[[@CR18]\].

Conclusions {#Sec12}
===========

Our kernel-based variance component test was able to prioritize noncoding variation from whole-genome sequencing data based on their potential to regulate gene expression. An allele-specific chromatin accessibility measure was used as both a biologically meaningful filter for the selection of the variants and the weight of each variant in the covariance kernel. We observed compelling evidence to support the idea that four genes might be *cis*-regulated by the SNPs we identified in them.
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